Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

Pluvicto, a prostate cancer drug, has gained expanded approval that triples the number of patients with metastatic disease ...

The FDA approved agents in MIBC and neuroendocrine tumors and amivantamab/lazertinib continues to shine in NSCLC.

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

Bristol Myers Squibb said the Food and Drug Administration approved Opdivo plus Yervoy as a first-line treatment for certain types of carcinoma.

Common adverse reactions included fatigue, diarrhea, and pain, with similar profiles across treatment arms ... colorectal cancer. The FDA has approved nivolumab (Opdivo; Bristol Myers Squibb ...

(RLTs are a form of targeted nuclear medicine ... (ARPIs), a class of drugs used in the treatment of metastatic prostate cancer. Pluvicto first got FDA approval on March 23, 2022, but this new ...

FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free ...

Johnson & Johnson's much-touted crop of bispecific antibodies for cancer generated its ... bluebird bio have also claimed approval for their BCMA-targeted CAR-T therapy Abecma (idecabtagene ...